Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2003;92:345-347
doi: 10.1161/01.RES.0000061765.06145.10
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bornfeldt, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bornfeldt, K. E.
Related Collections
Right arrow Restenosis
Right arrow Smooth muscle proliferation and differentiation
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2003;92:345.)
© 2003 American Heart Association, Inc.


Editorials

The Cyclin-Dependent Kinase Pathway Moves Forward

Karin E. Bornfeldt

From the Department of Pathology, University of Washington School of Medicine, Seattle, Wash.

Correspondence to Karin E. Bornfeldt, Department of Pathology, Box 357470, University of Washington School of Medicine, Seattle, WA 98195-7470. E-mail bornf@u.washington.edu


Key Words: migration • cyclin-dependent kinase inhibitor • retinoblastoma protein • smooth muscle cells


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

The cell cycle of mammalian cells is divided into four phases: G1 (first gap), S (DNA synthesis), G2 (second gap), and M (mitosis). Quiescent cells that have not entered the cell cycle are referred to as being in G0. Progression through the cell cycle requires the activation of cyclin-dependent kinases (CDKs). CDK activation is dependent on the association of the CDK with a cyclin regulatory subunit. Cyclin D/CDK4, cyclin D/CDK6, and cyclin E/CDK2 regulate transition through G1, cyclin A/CDK2 regulates S phase transition, and cyclin A/CDK2 and cyclin B/CDK2 regulate G2/M transition,1 as shown by the Figure. The activity of CDKs is also regulated by endogenous CDK inhibitors (CKIs) in the cyclin/CDK complex1 (Figure). Two families of CKIs have been characterized according to their structures and CDK targets. Kip/Cip proteins (p21Cip1, p27Kip1, and p57Kip2), which bind to both cyclin and CDK subunits, inhibit cyclin E- and A-dependent kinases but act as positive regulators of cyclin D-dependent kinases. The INK family of proteins (p16INKa, p15INKb, p18INKc, and p19INKd) exclusively binds to and inhibits CDK4 and CDK6.1


Figure Removed (Available Only in the Full Text)
View larger version (32K):
[in this window]
[in a new window]
 
How does the cell cycle control cell migration? Cells in mid-late G1 have the greatest ability to migrate, whereas cells in the G0, S, G2, and M phases are stationary. Overexpression of CKIs (p21Cip1 and p27Kip1) blocks CDK2 activity, G1 to S transition, and migration of SMCs. Furthermore, as shown by the studies of Díez-Juan and Andrés,16 overexpression of . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
FASEB J.Home page
V. I. Patel, S. Daniel, C. R. Longo, G. V. Shrikhande, S. T. Scali, E. Czismadia, C. M. Groft, T. Shukri, C. Motley-Dore, H. E. Ramsey, et al.
A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia
FASEB J, July 1, 2006; 20(9): 1418 - 1430.
[Abstract] [Full Text] [PDF]